Trial · NCT05809180
Pro-miniCHOP-like Regimen for Treatment-naive Elderly Patients
NCT05809180, Not applicable, Unknown, The First Affiliated Hospital of Soochow University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Pro-miniCHOP-like Regimen for Treatment-naive Elderly Patients. Trials, record NCT05809180. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05809180
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pro-miniCHOP-like Regimen for Treatment-naive Elderly Patients
- NCT number
- NCT05809180
- Status
- Unknown
- Phases
- Not applicable
- Enrollment
- 35 participants, estimated
- Lead sponsor
- The First Affiliated Hospital of Soochow University
- Conditions
- Diffuse Large B Cell Lymphoma
- Interventions
- Rituximab, Orelabrutinib, Pomalidomide, Pro-miniCHOP-like regimen, R-miniCHOP-like regimen
- First posted
- 2023-04-12
- Last updated
- 2023-04-20
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall Response Rate(ORR) after Pro-miniCHOP-like regimen | At the end of cycle 6 (each cycle is 21 days) | The rate of patients who achieved complete response and partial response after Pro-miniCHOP-like regimen. |
| Primary | Complete Response Rate(CRR) after Pro-miniCHOP-like regimen | At the end of cycle 6 (each cycle is 21 days) | The rate of patients who achieved complete response after Pro-miniCHOP-like regimen. |
| Secondary | Incidence of treatment-emergent adverse events, treatment-related adverse events and serious adverse events | Initiation of study drug until 28 days after last dose | The safety and tolerability of the therapeutic regimen measured by the incidence of Treatment-Emergent Adverse Events, Treatment-Related Adverse Events and Serious Adverse Events. |
| Secondary | Overall Response Rate(ORR) after Pro induction regimen | At the end of a cycle 1 of induction therapy period (each cycle is 21 days) | The rate of patients who achieved complete response and partial response after Pro induction regimen. |
| Secondary | Complete Response Rate(CRR) after Pro induction regimen | At the end of a cycle 1 of induction therapy period (each cycle is 21 days) | The rate of patients who achieved complete response after Pro induction regimen. |
| Secondary | Overall Survival (OS) | Up to 2 years after the end of last patient's treatment | OS will be assessed from the first drug given to date of death or end of follow-up. |
| Secondary | Progression Free Survival (PFS) | Up to 2 years after the end of last patient's treatment | PFS will be assessed from the first drug given to date of progression, relapse, death or end of follow-up. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05809180
GET https://conductscience.org/api/trials/v1/NCT05809180/registered